High expressions of TMEM173 (HR, 0.53; 95% CI 0.30–0.92; P = 0.024), FADD (HR, 0.65; 95% CI 0.42–1.00; P = 0.0495), and ERCC2 (HR, 0.50; 95% CI 0.31–0.80; P = 0.004) were significantly associated with better overall survival in patients with recurrent GBM. Here, ERCC2 is linked to glioblastoma.